TMU host REACTA Forum to discuss post-pandemic development of clinical trails

In November 2021, Taipei Medical University hosted REACTA Virtual Forum 2021 & TMU Clinical Trial Alliance Conference.

In this hybrid event, more than 20 experts with outstanding clinical trial experience and achievements from Taiwan, South Korea, Japan, Malaysia, and Thailand were invited to speak. The issues around post-pandemic management and the development of clinical trials were also discussed, sparking much cooperation.

This year’s conference was conducted both physically and remotely.

Keynote speaker, David Lee, Chief Scientific Officer at Novartis (Taiwan) Co., Ltd., shared the layout and global perspectives of international pharmaceutical companies in new drug development and gave a new perspective on future global market planning and development under the pandemic.

The conference also covered strengths and collaboration potentials from a number of participating organizations and hospitals, including TMU Clinical Trial Alliance, Taipei City Hospital, En Chu Kong Hospital, Taoyuan General Hospital, Ministry of Health and Welfare Tungs’ Taichung MetroHarbor Hospital, Chia-Yi Christian Hospital, Show Chwan Memorial Hospital, Chi Mei Medical Center, and Saint Mary’s Hospital Luodong.

This conference initiated the cross-sector dialogue and created opportunities for international research collaboration, stimulating research of development of drugs, medical devices, indications, and the development and applications of AI technology and continuously promoting international clinical trials in East Asia, and clinical trials with industrial value, thereby enhancing the quality of life and health of the region.

TMU President Chien-Huang Lin (林建煌) (photo on the left), and David Lee (photo on the right) delivering a speech.